



THE PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE

Harvard Medical School Task Force on Medical Countermeasures: Partnering for Public Good

Biographies of Task Force Members

Moderator



Kendall Hoyt, Assistant Professor at Dartmouth's Geisel School of Medicine at Dartmouth College

Kendall Hoyt is an Assistant Professor at the Geisel School of Medicine at Dartmouth and a Lecturer at the Thayer School of Engineering at Dartmouth College where she teaches courses on health systems, technological innovation, and biosecurity. Her research is focused on global health security and vaccine development strategy. She has served as a consultant for the Coalition for Epidemic Preparedness Innovations and the Nuclear Threat Initiative and as a member of the National Academies of Sciences Committee on the Department of Defense's Programs to Counter Biological Threats. She is the author of *Long Shot: Vaccines for National Defense*, Harvard University Press, 2012.

US Government:



Rick Bright, PhD, Advisor, President-elect Biden's Task Force on COVID ; Dr. Bright joined BARDA in 2010 and in his role manages a portfolio of projects for advanced development of vaccines, antiviral drugs, diagnostics and respirator devices to aid in the response and protection against pandemic and seasonal influenza. He also leads the BARDA Influenza Division International program, supporting programs to build and enhance global capacity for influenza vaccine production and evaluation in developing countries. Dr. Bright serves as an international subject matter expert on influenza, vaccine and antiviral drug development and diagnostic programs. He also serves as an advisor to the World Health Organization and the US Department of Defense.

Dr. Bright began his career in influenza vaccine and antiviral development during a nine year combined tenure at the US Centers for Disease Control and Prevention, Influenza Division. At the CDC, he focused on avian and human influenza viruses from multiple perspectives including immunology and vaccine development, viral pathogenesis and molecular correlates of pathogenicity, as well as antiviral drugs and the development novel assays for high throughput surveillance for resistance to antiviral drugs. Dr. Bright was a recipient of the Charles C. Shepard Science Award for Scientific Excellence. Dr. Bright has also worked in the biotechnology industry where he served as the Director of Immunology at Altea Therapeutics and Vice President of Research and Development and Global Influenza Programs at Novavax, Inc. In 2008, Dr. Bright joined PATH as the Scientific Director of the Influenza Vaccine Project in the Vaccine Development Global Program and the Director of the Influenza Vaccine Capacity Building Project in Vietnam. In this capacity, he provided technical leadership to accelerate the development of innovative vaccine and adjuvant candidates



THE PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE

against influenza to ensure protection and access to vaccines for populations of developing countries. Dr. Bright received his PhD in Immunology and Molecular Pathogenesis from Emory University (Atlanta, GA) and his BS in Biology (Medical Technology) and Physical Sciences from Auburn University (Montgomery, AL).

Private Sector:



Philip R. Dormitzer, MD, PhD, Vice President and Chief Scientific Officer Viral Vaccines, Pfizer. Dr. Dormitzer leads Pfizer viral vaccines research and development programs. These programs include the Pfizer-BioNTech RNA-based COVID-19 pandemic vaccine and influenza vaccine collaborations. The COVID-19 vaccine is in phase 3 clinical development, recently reported a positive interim analysis, and is being manufactured. A prefusion F-based RSV vaccine to protect infants through maternal immunization has been advanced from discovery to a global phase 3 clinical trial in pregnant women. A cytomegalovirus vaccine candidate is preclinical. Before joining Pfizer, Dr.

Dormitzer held positions at Novartis Vaccines that included Head of US Research. He was the founding member of the Novartis Viral Vaccine Research Center in Cambridge, MA. In 2009, his research team supported the development and licensure of three H1N1v influenza pandemic vaccines in the most rapid vaccine response in history, prior to the current COVID-19 pandemic. In 2013, his team responded to the H7N9 influenza outbreak by supplying the US pre-pandemic stockpile with a vaccine generated from a synthesized virus. Before joining industry, Dr. Dormitzer was an Assistant Professor of Pediatrics at Harvard Medical School and led a structural virology laboratory, which, with collaborators, determined the structures of the rotavirus neutralization antigens. He graduated summa cum laude in Anthropology from Harvard College; conducted paleontological research in Pakistan and studied the Efe Pygmies in Zaire; obtained a Ph.D. in Cancer Biology and an MD at Stanford University; completed Internal Medicine training at Massachusetts General Hospital; and completed the Harvard Infectious Diseases Program clinical fellowship.



Rebecca Fish, President, Hart Ledge Consulting, which focuses on global health security, vaccine development and commercialization strategies, and public-private partnerships. She has over 25 years of experience in healthcare working in both the private and public sectors. Rebecca has worked for global vaccine manufacturers including Merck & Co., Inc. and GlaxoSmithKline, and smaller biotechnology firms like Emergent BioSolutions. She has held a variety of senior policy and commercial positions including Vice President of Global Public Health Policy and Global Head of Medical Countermeasures. Rebecca

has also worked within the public sector as the Senior Policy Advisor in the National Vaccine Program Office within the U.S. Department of Health and Human Services, and at the Centers for Medicare and Medicaid Services. Rebecca graduated with a High Honors degree from Mount Holyoke College. She received her M.B.A. from Duke University's Fuqua School of Business and



THE PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE

served as a member of the Fuqua Health Care Advisory Board. Rebecca was a Fellow in the Emerging Leaders in Biosecurity program through the Johns Hopkins Center for Health Security.



Arpa (Shah) Garay, President, Global Pharmaceuticals, Commercial Analytics, Digital Marketing at Merck & Co. Arpa Garay is a senior executive with 20 years of healthcare general management experience across geographies, therapeutic areas, and product lifecycle. Her career reflects extensive success in consistently driving business growth to exceed financial expectations, innovation to reflect an evolving global healthcare environment, strategic insight to drive M&A decisions, and leadership to build and inspire diverse, talented teams. Arpa is currently the President of Global Pharmaceuticals, Commercial Analytics, and Digital Marketing at MSD (the tradename of Merck & Co., Inc). She leads the commercialization of in-line and pipeline assets as well as business development across the specialty, hospital, and chronic care businesses, totaling ~\$20bn / 50% of net sales for the company. Additionally, she is responsible for data analytics, digital marketing, and partnerships worldwide for headquarters as well as country operations.

Prior to this role, Arpa was Senior Vice President, US Vaccines, where she collaborated with policy makers, the BIO Industry Association, and public health organizations to drive growth across the vaccines portfolio. She also led the company's business in Norway as Managing Director, where she worked closely with the government on healthcare policy, developed innovative approaches to securing patient access, and led the subsidiary to become the #1 pharmaceutical company in the country, which was a first around the world. Arpa also brings significant US healthcare experience through a variety of roles at both Merck and Bristol-Myers Squibb.

Arpa started her career as a management consultant at Monitor Group (now Monitor Deloitte), gaining significant experience across industries and business challenges. She has been externally recognized for her leadership as Fortune's Most Powerful Women: Next Gen, Business Insider's Global Top 30 under 40 in BioPharma, and Philadelphia Business Journal's Top 40 under 40 business leaders. Arpa holds a Bachelor of Science in Economics from the Massachusetts Institute of Technology, where she focused on medicine, public health and public policy. She has lived in five countries, visited seventy, and loves to travel with her husband and three children every chance she gets.



Jonathan P. Gertler, MD, is Co-Founder, Managing Partner and CEO of Back Bay Life Science Advisors and Managing Director, BioVentures Investors MedTech Funds. He has over 30 years of clinical and scientific experience, and extensive advisory work with biotechnology, diagnostic, medical device and health care IT companies in both the private and public sector. A former vascular surgeon and founder of several life science companies, Dr. Gertler is a frequent speaker and writer on strategic issues facing life science companies at all stages. Before founding Back Bay in 2010, Dr. Gertler served as Senior Partner and Managing Director of Leerink Swann Strategic Advisors, Head of BioPharma Investment Banking at Leerink Swann & Company, as well as Head of Life Science Investment Banking at Adams Harkness/Canaccord Adams. Dr. Gertler founded Antyllus Therapeutics, a development-stage



THE PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE

biotechnology company focused on aortic diseases, and Biofeedback Systems Design, a digital medicine company developed for the wellness market. Dr. Gertler also founded Cardiovascular Technologies, which successfully exited in 2001. Dr. Gertler was an academic vascular surgeon, primarily as Associate Professor of Surgery at Harvard Medical School and the Massachusetts General Hospital. Dr. Gertler trained at Yale in General Surgery and at the Massachusetts General Hospital in Vascular Surgery. He earned a medical degree from Columbia University College of Physicians and Surgeons, an MBA in Health Policy and Management from Boston University and a BA from Wesleyan University. He is a Fellow of the American College of Surgeons and a member of numerous academic and clinical surgical societies. He is a Series 24 Registered Securities Principal.



Robert V. House, PhD, FATS, is Senior Vice President, Government Contracts at Ology Bioservices, Inc. Robert V. House, PhD, FATS at Ology Bioservices .Dr. House joined Ology Bio in June 2014 as Senior VP of Government Contracts. Previously, Dr. House worked for more than 11 years at DynPort Vaccine Company in Frederick, Md., where he held the positions of VP of Science and Technology, Chief Scientific Officer and President. During this time he developed extensive experience in winning and managing large USG-funded programs for developing medical countermeasures. He previously worked at Covance Laboratories in Madison, Wis. and IIT Research Institute in Chicago, Ill., where he managed highly successful programs in immunotoxicology assessment.

Dr. House has nearly 30 years' experience in basic and applied biomedical research and development, specializing in the assessment of inadvertent and therapeutic immunomodulation. Dr. House earned a BA in zoology and an MSPH and PhD from the University of North Carolina at Chapel Hill. He is the author/ co-author of more than 100 journal articles and 28 book chapters and editor of two books in the fields of immunomodulation, immunotoxicology, host defense, cytokine biology and biodefense. Dr. House is an adjunct professor at George Mason University where he teaches graduate courses in medical countermeasure development. He is a fellow of the Academy of Toxicological Sciences.



Ryan Morhard is with Ginkgo Bioworks where he works on Concentric. Concentric uses Ginkgo's synthetic biology platform to provide large-scale testing and support development of vaccines and therapeutics. Before joining Ginkgo Bioworks, Ryan led the World Economic Forum's work on global health security and biological risks. Prior to that, Ryan served as Branch Chief for International Partnerships at HHS. In this role, Ryan led engagement in several multilateral, regional, and bilateral partnerships to support domestic and international response to Ebola, Zika, and other public health emergencies, as well as to strengthen collective preparedness. Before that, Ryan was a Legal Analyst and Associate at the Center for Health Security. Ryan received his law degree from Washington University in St. Louis and studied Neuroscience at the University of Pittsburgh.



THE PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE



Jake Reder, PhD, CEO, Celdara Medical and Pandemic Security Initiative. Jake cofounded Celdara Medical with Prof. Michael Fanger as a way to bridge academic innovation and the marketplace, and currently serves as Director and CEO. Jake guided CM from a concept to the fastest growing company (across all sectors) in the state three years in a row, and is now applying these learnings to the Pandemic Security Initiative. He serves on the Boards of the New Hampshire Academy of Science, Virtici, and MBV, and is Chairman of CairnSurgical, and Javelin Oncology. Jake has lived, studied and worked in Canada, Germany, and the USA, with experiences in research, venture investing, corporate alliances and internal startups, academia, and startups. In 2017 Jake was selected by the US SBA as NH Small Business Person of the Year. Jake earned a B.Sc. with First Class Honors from the University of Waterloo, and a PhD in Chemistry as a Brown-Wetherill Fellow at Purdue University and Ludwig Maximilians Universität. Jake enjoys skiing, hiking, and sailing with his children.

Non-Profit:



Katrine Thor Andersen, deputy director, strategy planning and management for the Tuberculosis and Global Health strategy, planning and management teams, at the William and Melinda Gates Foundation, is responsible for the team's strategy and business operations. Prior to joining the foundation in 2017, Katrine held senior leadership positions leading global business transformation at Global Research, Novo Nordisk. The projects that she led include organization development, operational excellence, R&D informatics, outsourcing, and portfolio management. Katrine has been engaged in drug development since 1998 and held positions across the product development value chain at Bristol Myers Squibb, Novo Nordisk, and LEO Pharma. She worked as a pharmaceuticals research scientist and product project leader for 8 years, followed by working as a regulatory affairs transformation consultant, R&D outsourcing manager and R&D chief of staff. She also has experience in regulatory affairs in the public sector through her work at the Danish Medicine Agency. Katrine is passionate about innovation and has served as business strategy advisor to startups within eHealth and scientific IT. Katrine holds MBA from Copenhagen Business School, an MSc Quality Assurance & Regulatory Affairs from Temple University, and an MSc Pharmacy from the Royal Danish School of Pharmacy.



Julia Barnes-Weise, J.D., CLP, Executive Director of the Global Healthcare Innovation Alliance Accelerator, co-founded the non-profit GHIAA in the spring of 2016 as a spin out of her work at Duke University as a Visiting Associate Professor of the Practice at Duke's Sanford School of Public Policy, and Director of the Sanford Innovation, Technology Policy project. The GHIAA MAPGuide, an online guide to global health agreements, was launched in August 2020. www.ghiaa.org. She has been a Senior Business



THE PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE

Development and Legal Consultant for the Coalition for Epidemic Preparedness Innovations (CEPI) for over three years and was recently inducted as a board member of the Licensing Executive Society. As a consultant to the World Health Organization on partnering for the Pandemic Preparedness Framework initiative, she co-authored a paper on the success and failures of the Ebola Outbreak 2014 consortia and created a system for monitoring potential Priority Pathogen development partnerships. She is a Collaborator with the Harvard University's Berkman Klein Center Global Access in Action initiative and is a frequent speaker on healthcare licensing and partnering. She is also a Consultant and lecturer for the Duke Law School Access to Medicines seminar; and a former Board Member of the Medical University of South Carolina Foundation for Research and Development. She was formerly a Director of Business Development at Glaxo Wellcome (now GSK) and an attorney at SAS Institute.



Thomas J. Bollyky is director of the global health program and senior fellow for global health, economics, and development at the Council on Foreign Relations (CFR). He is also an adjunct professor of law at Georgetown University. Bollyky is the author of the book *Plagues and the Paradox of Progress: Why the World is Getting Healthier in Worrisome Ways* and the founder and managing editor of *Think Global Health*, an online magazine that examines the ways health shapes economies, societies, and everyday lives around the world. Prior to coming to CFR, Bollyky served in a variety of positions in the U.S. government, most recently at the Office of the U.S. Trade Representative (USTR). He led the negotiations on medical technology regulation in the U.S.-Republic of Korea Free Trade Agreement and represented USTR in the negotiations with China on the safety of food and drug imports. Bollyky was a Fulbright scholar to South Africa, where he worked as a staff attorney at the AIDS Law Project, and an attorney at Debevoise & Plimpton LLP, where he represented clients before the International Court of Justice and the U.S. Supreme Court. Bollyky is a former law clerk to Chief Judge Edward R. Korman and was a health policy analyst at the U.S. Department of Health and Human Services. Bollyky received his BA in biology and history at Columbia University and his JD at Stanford Law School, where he was the president of the *Stanford Law & Policy Review*. He is a member of the New York and U.S. Supreme Court bars.



Bruce Gellin, MD, MPH, President, Global Immunization, Sabin Vaccine Institute. Prior to joining Sabin, Bruce served as the Deputy Assistant Secretary for Health and Director of the National Vaccine Program Office at the U.S. Department of Health and Human Services (HHS), where he was the principle technical, strategic and policy advisor to the Assistant Secretary for Health on all aspects of the National Vaccine Program. In this role, Bruce served as a technical and policy advisor to the World Health Organization, focusing on influenza vaccines and global issues of vaccine hesitancy. Prior to joining HHS, Bruce founded and served as executive director of the National Network for Immunization Information, worked as a medical officer at the National Institute of Allergy and Infectious Diseases, served as Epidemic Intelligence Service officer at the Centers for Disease Control and Prevention (CDC), and was a Luce Scholar in the Philippines. Bruce's global health work includes consulting for Gavi, the Vaccine



THE PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE

Alliance, chairing the World Health Organization's Global Action Plan for Influenza Vaccines Advisory Group, working with the Children's Vaccine Initiative, and serving as a Warren Weaver fellow at the Rockefeller Foundation. He is one of the nation's principle spokespersons on vaccines and immunizations and has served as on the faculty at Johns Hopkins Bloomberg School of Public Health, Columbia University's Mailman School of Public Health and Vanderbilt University Medical School. He recently was appointed to Georgetown University Medical Center's Department of Medicine as an adjunct professor in the Division of Infectious Diseases.

In 1991, Bruce earned a master's degree in public health in epidemiology from the Columbia University Mailman School of Public Health. He is a graduate of Weill Cornell Medical College and was a Morehead Scholar at the University of North Carolina at Chapel Hill. He completed his internship and residency in internal medicine at Vanderbilt University and later was a preventive medicine resident at Cornell and at the CDC's Arctic Investigations Program in Anchorage, Alaska. Bruce achieved board certification in internal medicine and infectious diseases, is an active member of numerous professional organizations, and serves as a peer reviewer for over a dozen medical journals. In 2016, the Infectious Diseases Society of America awarded Bruce with the Society Citation in recognition of his work in the field of infectious diseases, and in 2015, he was bestowed the honor of the American Medical Association's Nathan Davis Award for Outstanding Government Service for his leadership and vision while overseeing our nation's vaccine and immunization initiatives.



Heather Ignatius is the Director of US and Global Policy and Advocacy at PATH. She oversees PATH's Advocacy and Public Policy Department and its work to influence global priority setting, enact policies and secure public resource allocation to bring evidence-based innovations and interventions to scale. A veteran advocate and public policy specialist, Ms. Ignatius leads a global team of advocates working to engage decision makers and influencers, strengthen advocacy coalitions and increase the use of evidence in policy making.

Ms. Ignatius joined PATH in 2012, to lead PATH's US public policy portfolio. In this role she educated and engaged elected officials and executive branch agency leadership, created strategic partnerships with for-profit and non-governmental partners, and developed policy recommendations to strengthen US leadership and support for global health programs. Ms. Ignatius joined PATH from the Global Alliance for TB Drug Development where she led initiatives to create an enabling policy environment, mobilize resources, and engage key stakeholders to advance the organization's mission of developing and ensuring access to new shorter-course TB regimens for people in low- and middle-income countries. Prior to her experience in the health sector, Ms. Ignatius worked on a variety of international and social sector issues at the United Nations Foundation, the National Endowment of Democracy and the Women's Research and Education Institute. A Silicon Valley native, she started her career in the tech sector, working for Cisco Systems. She holds a bachelor's degree in political science from the University of California, San Diego and a master's degree from the Elliot School of International Affairs at The George Washington University.



THE PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE



James (Jim) Robinson, Vice Chair of the Coalition for Epidemic Preparedness Innovations (CEPI). Robinson manages the CEPI manufacturing strategy for a COVID-19 vaccine. Robinson began his career as a biochemical engineer with G.D. Searle and worked at various companies before becoming the head of technical support for Merck's vaccine, biologics and sterile manufacturing in 2010.



Charlie Weller, Head of Vaccines, Wellcome Trust, has been head of the vaccine's priority platform and head of epidemics since the start of 2017. She led the development of the vaccine's strategy at the Wellcome Trust during 2016, as part of the Trust's new strategic framework. Charlie joined the Wellcome Trust in 2014 as a Senior Portfolio Developer, where she oversaw the Immunology portfolio, led the funding response to the Ebola epidemic of 2014-2015 and contributed to strategy development in preparedness for future epidemics, prior to taking the lead on vaccines and epidemics. Charlie has over 16 years of research experience in both academic and pharmaceutical environments, ranging from host pathogen interactions to cellular and molecular immunology. Before joining the Wellcome Trust, Charlie was a laboratory head at Novartis Institute for Biomedical Research engaged in target identification and validation within the respiratory disease area, focusing on innate immune responses in respiratory exacerbations. Prior to this, Charlie investigated mast cell localization and function in health, respiratory disease and parasite infections as a postdoctoral fellow at Imperial College London. She holds a BSc in genetics at Birmingham University, and a PhD in Immunology at Imperial College London.



THE PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE

As health emergencies become more frequent and their consequences graver, we require a new, holistic approach to policy making. We advocate an approach that is tantamount to building a global immune system—one comprised of multi-sector governing bodies and effective and well-resourced health systems to prevent and mitigate health security threats.

The mission of the Program in Global Public Policy and Social Change (PGPPSC), an initiative of the Department of Global Health and Social Medicine at Harvard Medical School is to prepare multidisciplinary leaders to take on the existential challenges of health security, to implement sound policy to protect and serve the best interests of a global population. By creating a resonant voice and policy hub for global health practitioners, PGPPSC aims to foster coordination among the deeply intertwined health, diplomacy, and security communities, to address global health threats through strong and well governed health systems.

The PGPPSC team consists of seasoned health and policy professionals working closely with Paul Farmer, MD, PhD, Kolokotronis University Professor and chair of the Department of Global Health and Social Medicine. We bring a wealth of experience in frontline healthcare delivery in fragile settings, as well as a deep grounding in policy formulation and advancement for the most pressing social issues.



Vanessa Kerry, MD, MSc, Program Director, Harvard Medical School Program in Global Public Policy and Social Change. Dr. Kerry is the founder and CEO of Seed Global Health, a non-profit that invests in health system strengthening by training needed health professionals in resource limited settings; these health professionals can not only provide quality care but can help train others ensuring there is pipeline of doctors, nurses and midwives for future generations. She is also a physician at

Massachusetts General Hospital and serves as the associate director of Partnerships and Global Initiatives at the hospital's Center for Global Health. Dr. Kerry graduated from Yale University summa cum laude and Harvard Medical School cum laude, completing her internal medicine residency and critical care fellowship at Massachusetts General Hospital. She earned her Master's in Health Policy, Planning, and Financing from the London Schools of Economics and of Hygiene and Tropical Medicine.



Margaret Bourdeaux, AB '97, MD, MPH '09, is Research Director, Harvard Medical School Program in Global Public Policy and Social Change; Research Fellow, Harvard Law School, Berkman Klein Center for Internet and Society; Research Director, Harvard Kennedy School Belfer Center for Science and International Affairs. Her research and fieldwork focus on health systems and institutions in conflict-affected states. She has worked with the Office of the Secretary of Defense Policy to analyze the US Department of Defense's global health projects and programs. She led a joint Harvard-NATO team of analysts to evaluate the impacts, challenges, and opportunities international

security forces have in protecting and rebuilding health systems in conflict-affected states. Dr. Bourdeaux earned her BA at Harvard University, her MD at Yale Medical School, completed her combined residency in Internal Medicine and Pediatrics at Brigham and Women's Hospital in Boston,



THE PROGRAM IN GLOBAL PUBLIC POLICY AND SOCIAL CHANGE

MA, and completed her MPH at Harvard T.H. Chan School of Public Health. She was one of the first graduates of the Global Women's Fellowship at Brigham and Women's Hospital.



Annmarie Sasdi, Director of Policy and Partnerships, Harvard Medical School Program in Global Public Policy and Social Change. Prior to this role, she was the senior director for new program development at the Harvard Kennedy School Division of Executive Programs. In this capacity, she worked with leading faculty from across Harvard institutions to research and design curriculum for training programs for senior public officials and policymakers from around the world. Previously, she held a Senior Fellowship at the Harvard Kennedy School Mossavar-Rahmani Center for Business and Government. Prior to coming to Harvard, she spent 25 years in the financial services sector, most recently as an executive director in investment banking at Goldman Sachs International in London. She received her master's degree (MCRP) from the Harvard Kennedy School and her BA, honors, from Princeton University, School of Architecture and Urban Planning.